scPharmaceuticals (SCPH) Competitors $3.86 -0.11 (-2.77%) Closing price 04:00 PM EasternExtended Trading$3.86 0.00 (0.00%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SCPH vs. CMRX, CDMO, AVXL, SION, QURE, AVBP, CRON, XERS, PHAR, and REPLShould you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include Chimerix (CMRX), Avid Bioservices (CDMO), Anavex Life Sciences (AVXL), Sionna Therapeutics (SION), uniQure (QURE), ArriVent BioPharma (AVBP), Cronos Group (CRON), Xeris Biopharma (XERS), Pharming Group (PHAR), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. scPharmaceuticals vs. Its Competitors Chimerix Avid Bioservices Anavex Life Sciences Sionna Therapeutics uniQure ArriVent BioPharma Cronos Group Xeris Biopharma Pharming Group Replimune Group Chimerix (NASDAQ:CMRX) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment. Which has better valuation and earnings, CMRX or SCPH? Chimerix has higher earnings, but lower revenue than scPharmaceuticals. Chimerix is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChimerix$212K3,778.71-$82.10M-$0.99-8.63scPharmaceuticals$36.33M5.61-$85.15M-$1.91-2.02 Do insiders and institutionals hold more shares of CMRX or SCPH? 45.4% of Chimerix shares are owned by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are owned by institutional investors. 13.1% of Chimerix shares are owned by company insiders. Comparatively, 4.8% of scPharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor CMRX or SCPH? In the previous week, Chimerix's average media sentiment score of 0.00 equaled scPharmaceuticals'average media sentiment score. Company Overall Sentiment Chimerix Neutral scPharmaceuticals Neutral Do analysts recommend CMRX or SCPH? Chimerix currently has a consensus target price of $8.53, suggesting a potential downside of 0.08%. scPharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 262.69%. Given scPharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe scPharmaceuticals is more favorable than Chimerix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chimerix 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CMRX or SCPH more profitable? Chimerix has a net margin of 0.00% compared to scPharmaceuticals' net margin of -216.24%. Chimerix's return on equity of -50.78% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ChimerixN/A -50.78% -44.94% scPharmaceuticals -216.24%-594.07%-73.54% Which has more volatility & risk, CMRX or SCPH? Chimerix has a beta of -0.17, suggesting that its stock price is 117% less volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. SummaryChimerix and scPharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPH vs. The Competition Export to ExcelMetricscPharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$209.58M$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.07%P/E Ratio-2.0220.3027.1920.03Price / Sales5.61251.54414.39108.98Price / CashN/A41.7026.2128.59Price / Book14.307.397.925.55Net Income-$85.15M-$55.04M$3.17B$248.49M7 Day Performance1.31%3.01%2.18%5.37%1 Month Performance-8.10%-0.21%1.25%6.63%1 Year Performance-12.47%4.48%33.90%21.20% scPharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPHscPharmaceuticals4.1189 of 5 stars$3.86-2.8%$14.00+262.7%-10.0%$209.58M$36.33M-2.0230Positive NewsCMRXChimerix0.6253 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6757 of 5 stars$12.50+0.1%$12.25-2.0%+68.4%$799.18M$139.91M-5.23320High Trading VolumeAVXLAnavex Life Sciences3.567 of 5 stars$9.22-2.7%$44.00+377.2%+155.8%$787.13MN/A-16.7640Positive NewsSIONSionna TherapeuticsN/A$17.35+9.5%$38.50+121.9%N/A$765.48MN/A0.0035Positive NewsQUREuniQure2.0872 of 5 stars$13.94+0.6%$37.82+171.3%+277.2%$763.63M$27.12M-3.18500AVBPArriVent BioPharma1.7212 of 5 stars$21.77-5.0%$40.00+83.7%+11.6%$744.75MN/A-5.7740CRONCronos Group1.977 of 5 stars$1.91+0.5%N/A-8.5%$736.65M$117.61M14.69450XERSXeris Biopharma3.594 of 5 stars$4.67-0.6%$6.25+33.8%+125.4%$730.30M$203.07M-15.57290Positive NewsPHARPharming Group2.7013 of 5 stars$10.68-2.9%$30.00+181.0%+27.7%$726.29M$297.20M-53.38280High Trading VolumeREPLReplimune Group4.1499 of 5 stars$9.29-0.4%$20.83+124.3%+16.5%$719.22MN/A-3.03210 Related Companies and Tools Related Companies Chimerix Alternatives Avid Bioservices Alternatives Anavex Life Sciences Alternatives Sionna Therapeutics Alternatives uniQure Alternatives ArriVent BioPharma Alternatives Cronos Group Alternatives Xeris Biopharma Alternatives Pharming Group Alternatives Replimune Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPH) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
